Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

By Anthony C. Keech, P. Mitchell, P. Summanen, J. O'day, Tme Davis, Moffitt, Marja-Riitta Taskinen, R. J. Simes, D. Tse, E. Williamson and 6 more. The Lancet, 2007

1,027 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Ophthalmology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/9ae14091303fd1df6f72123a59c4eaf100838190

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. V. Basevi
2. J. Forbes
3. M. Cooper

In Ophthalmology

1. Daniel Shu Wei Ting
2. Tien Yin Wong
3. V. Basevi

In Radiology, Nuclear Medicine and Imaging

1. Daniel Shu Wei Ting
2. Tien Yin Wong
3. V. Basevi

Citations in the corpus

• Standards of Medical Care in Diabetes—2013 (2012, background): “Other emerging therapies for retinopathy include sustained intravitreal delivery of fluocinolone (373) and the possibility of prevention with fenofibrate (374,375).”
• Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review (2016, background): “004), and fewer had macular edema or laser treatments.(76) The use of fenofibrate, however, did not seem to correlate with the lipid level in the same study, suggesting that there may be an unknown protective effect of fenofibrate in DM patients.”
• Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss (2015, background): “In an ancillary study of the Fenofibrate Intervention and Event-lowering in Diabetes (FIELD) cohort, participants treated with fenofibrate had a 31 % reduced risk of requiring laser treatment for PDR or DME, compared to placebo [106].”
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, neutral): “Fenofibrate reduces the progression of diabetic retinopathy.(413,414)”
• Mechanisms of diabetic complications. (2013, background): “In the FIELD study (294), fenofibrate reduced laser treatment for macula edema and proliferative diabetic retinopathy.”